IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2024 | Buy → Neutral | BTIG Research | |
| 7/20/2021 | Overweight | Stephens | |
| 7/20/2021 | $27.00 | Overweight | Stephens & Co. |
| 7/20/2021 | Outperform | Cowen & Co. | |
| 7/20/2021 | $26.00 | Buy | BTIG |
HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef
10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
8-K - Alpha Teknova, Inc. (0001850902) (Filer)
424B3 - Alpha Teknova, Inc. (0001850902) (Filer)
EFFECT - Alpha Teknova, Inc. (0001850902) (Filer)
S-1 - Alpha Teknova, Inc. (0001850902) (Filer)
10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
8-K - Alpha Teknova, Inc. (0001850902) (Filer)
D - Alpha Teknova, Inc. (0001850902) (Filer)
8-K - Alpha Teknova, Inc. (0001850902) (Filer)
8-K - Alpha Teknova, Inc. (0001850902) (Filer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)
SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)
SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)
SC 13G - Alpha Teknova, Inc. (0001850902) (Subject)
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea
The Dow Jones index closed higher by more than 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Alpha Teknova The Trade: Alpha Teknova, Inc. (NASDAQ:TKNO) 10% owner Telegraph Hill Partners Management Company, LLC bought a total of 12,096,773 shares at an average price of $1.24. To acquire these shares, it cost around $15 million. The co
Stephens & Co. analyst Jacob Johnson reiterates Alpha Teknova (NASDAQ:TKNO) with a Overweight and maintains $5 price target.
Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million, down 17% to 18% when compared to second quarter 2023. However, when adjusted to remove an unusually large Clinical Solutions order, second quarter 2024 revenue increased by 7% to 9%. Teknova continues to anticipate Free Cash Outflow of less than $18 million for 2024 – with $3.0 to $3.4 million of total cash used in the second quarter of 2024. Teknova expects to report its complete financial results for the second quarter of 2024 on August 13th, 2024, following the close of market.
Stephens & Co. analyst Jacob Johnson reiterates Alpha Teknova (NASDAQ:TKNO) with a Overweight and maintains $5 price target.
Stephens & Co. analyst Jacob Johnson reiterates Alpha Teknova (NASDAQ:TKNO) with a Overweight and maintains $15 price target.
BTIG Research downgraded Alpha Teknova from Buy to Neutral
Stephens initiated coverage of Alpha Teknova with a rating of Overweight
Stephens & Co. initiated coverage of Alpha Teknova with a rating of Overweight and set a new price target of $27.00
Cowen & Co. initiated coverage of Alpha Teknova with a rating of Outperform
BTIG initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $26.00
Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2024. "Our year-on-year double-digit revenue growth in the third quarter gives us confidence that we have put Teknova on track f
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you woul
Second quarter 2024 total revenue was $9.6 million, up 3% sequentiallyRaised $15.4 million of equity capital in July 2024Launched two new offerings: Express-TekSM Production and RUO+ manufacturing gradeCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2024. "We delivered solid results across the board in the first half of 2024," said Stephen Guns
HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market. Teknova will host a webcast and conference call on Tuesday, August 13, 2024, beginning at 5:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like t
First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek™ Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2024. "I am pleased with our performance in the first quarter," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "Not only did we deliver solid results, but we su
HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market. Teknova will host a webcast and conference call on Monday, May 13, 2024, beginning at 5:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to parti
Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million HOLLISTER, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2023. "Our performance in 2023 validates the difficult but transformative changes we have made over the last twelve months," said
HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market. Teknova will host a webcast and conference call on Monday, March 11, 2024, beginning at 5:30 p.m. Eastern Time. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/m
HOLLISTER, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, following the close of market. Teknova will host a webcast and conference call on Thursday, November 9, 2023, beginning at 5:30 p.m. Eastern Time. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/n
Second quarter 2023 total revenue was $11.5 million, up 26% sequentiallyReceived certification of new state-of-the-art facility for production of GMP-grade productsCompany revises 2023 revenue guidance to $37-40 million, continues to anticipate free cash outflows of $30 million for full year HOLLISTER, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2023. "Today we reported strong operating results for the secon
Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2024. "Our year-on-year double-digit revenue growth in the third quarter gives us confidence that we have put Teknova on track f
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you woul
Second quarter 2024 total revenue was $9.6 million, up 3% sequentiallyRaised $15.4 million of equity capital in July 2024Launched two new offerings: Express-TekSM Production and RUO+ manufacturing gradeCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2024. "We delivered solid results across the board in the first half of 2024," said Stephen Guns
Express-TekSM Production enables customers to have their products enter production in days instead of weeks, significantly shortening turnaround time New manufacturing grade, RUO+, provides a seamless and cost-effective option for customers as they transition from RUO to GMP HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched two new offerings to provide customers with increased product customization options: Express-TekSM Production, to expedite the manufacturing and delivery
HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market. Teknova will host a webcast and conference call on Tuesday, August 13, 2024, beginning at 5:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like t
HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024. The gross proceeds to Teknova from the private placement are approximately $15.4 million, before deducting offering expenses paya
HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024. The private placement is expected to close on or about July 12, 2024, subject to the satisfaction of customary closi
Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today provided a business update including preliminary unaudited financial results for the second quarter ended June 30, 2024. "I'm excited to share our sustained progress in executing against our strategy," said Stephen Gunstream, President and Chief Executive Officer. "I'm increasingly confid
First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek™ Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2024. "I am pleased with our performance in the first quarter," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "Not only did we deliver solid results, but we su
First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times Novel, multi-purpose AAV stabilizer solution increases capsid yield up to 50% while safeguarding product integrity across the AAV purification workflow HOLLISTER, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched the Company's first custom product configurator, Build-TekTM